Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metreleptin in Patients Under 6 Years of Age With Generalised Lipodystrophy
NCT06502990Phase 3Terminated
- Sponsor
- Amryt Pharma
- Start
- May 2025
- Primary completion
- Feb 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
A Phase 3 trial of metreleptin in generalized lipodystrophy (GL), sponsored by Amryt Pharma. Started May 2025; status: terminated.
02
Drugs
metreleptin
03
Conditions
generalized lipodystrophy (GL)
Beyond the preview
Go deeper on NCT06502990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06502990.